Inova Launches Predictive Phenotyping Study with NIH
In case you missed it, PierianDx customer, Inova, is launching a joint study with the National Institutes of Health (NIH) to “re-engineer” genomics. The study, called the Genomic Ascertainment Cohort (TGAC), launched in early March, will collect the genomes of 10,00 people, and then use analytics to predict phenotypic outcomes using genes and gene variants identified in the genomes. 
Then, they will check their work. That is, they will follow up with study participants to see how accurate their predictions were. Participants with specific genotypes will be called in for phenotyping using blood and other clinical tests. Although not all of the participants will take part in follow up, all of them did give their express consent to participate.
Inova has contributed 8,000 mother-father-child trios from their extensive Longitudinal Childhood Genome Study. The other 2,000 genomes will come from institutes affiliated with the NIH as well as newly recruited patients.